Nalmefene Hydrochloride Hydrate

PreclinicalSmall molecule

Nalmefene Hydrochloride Hydrate is one of 46 small molecule programs targeting Alcohol Dependence. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcohol DependenceActive, not recruiting

Alcohol DependencePreclinical

Active, not recruiting

Competition

Competitive Landscape

116 competitors in Alcohol Dependence

#DrugCompanyPhaseTrials

Depakote

Zyprexa

2 3

Wellbutrin

GGlaxo Dba Glaxosmithkline

Phase 3

1 4

Tums

Otsuka

Phase 3

1 5

Inversine

TTargacept Inc.

Phase 3

1 6

Seroquel

AstraZeneca

Phase 3

1 7

Lioresal

Novartis

Phase 2

4 8

Byetta

AstraZeneca

Phase 2

2 9

Epidiolex

Jazz Pharmaceuticals

Phase 2

2 10

Alcohol

Astellas

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alcohol Dependence1 trial

Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients with Alcohol Dependence

Completed· Otsuka logo

Otsuka··NCT04107051·533 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nalmefene Hydrochloride Hydrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nalmefene Hydrochloride Hydrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nalmefene Hydrochloride Hydrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Otsuka company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Otsuka

Nalmefene Hydrochloride Hydrate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alcohol Dependence1 trial

References

Drug Info

Quick Facts

Related News